Reported $1.7 million in net product revenue for the fiscal second quarter and $5.6 million for the first half of fiscal 2026. Achieved 80% gross margins on LYMPHIR product sales. Net loss for the quarter was $26.6 million, significantly impacted by a $19.7 million one-time contract manufacturing organization (CMO) cancellation charge. Secured up to $36.5 million in combined debt and equity financing in May 2026 to support commercial operations. Maintained $2.6 million in cash and cash equivalents as of March 31, 2026, prior to the May financing. Expects current funds to support operations through November 2026.